BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 31848884)

  • 1. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
    Yang F; Anekpuritanang T; Press RD
    Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
    DiNardo C; Lachowiez C
    Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
    Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
    Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
    Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
    Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.
    Flach J; Shumilov E; Wiedemann G; Porret N; Shakhanova I; Bürki S; Legros M; Joncourt R; Pabst T; Bacher U
    Hematol Oncol; 2020 Oct; 38(4):425-431. PubMed ID: 32306411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
    Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of molecular MRD monitoring by next-generation sequencing in patients with
    Shumilov E; Flach J; Joncourt R; Porret N; Wiedemann G; Novak U; Gfeller E; Jeker B; Amstutz U; Pabst T; Bacher U
    Leuk Lymphoma; 2019 Oct; 60(10):2588-2590. PubMed ID: 30998101
    [No Abstract]   [Full Text] [Related]  

  • 11. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
    Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
    Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
    Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
    PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Relapsed Acute Myeloid Leukemia.
    Thol F; Ganser A
    Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.
    Shiba N; Yoshida K; Shiraishi Y; Okuno Y; Yamato G; Hara Y; Nagata Y; Chiba K; Tanaka H; Terui K; Kato M; Park MJ; Ohki K; Shimada A; Takita J; Tomizawa D; Kudo K; Arakawa H; Adachi S; Taga T; Tawa A; Ito E; Horibe K; Sanada M; Miyano S; Ogawa S; Hayashi Y
    Br J Haematol; 2016 Nov; 175(3):476-489. PubMed ID: 27470916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An NGS based MRD evaluation from acute myeloid leukemia patients.
    Chen B; Wang L; Wang Z; Zhang H; Chen L; Zhang L; Li J; Yan X; Zhao M; Lin Y; Ru K
    Int J Lab Hematol; 2023 Jun; 45(3):353-359. PubMed ID: 36751002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Tools for Diagnosis and Monitoring of AML.
    Guijarro F; Garrote M; Villamor N; Colomer D; Esteve J; López-Guerra M
    Curr Oncol; 2023 May; 30(6):5201-5213. PubMed ID: 37366878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of novel mutations in epigenetic modifiers in AML.
    Abdel-Wahab O; Patel J; Levine RL
    Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience.
    Steidl C; Aroldi A; Mologni L; Crespiatico I; Fontana D; Mastini C; Fumagalli M; Perfetti P; Borin L; Valentini C; Piazza R; Gambacorti-Passerini C
    Leuk Res; 2022 Jul; 118():106861. PubMed ID: 35653850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.